Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287724 · ClinicalTrials.gov registry record · Early Phase 1
Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli
A Early Phase 1 study of Pruritus and Skin Disorder, sponsored by Wright State University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05287724: Completed Early Phase 1 study of Pruritus and Skin Disorder, sponsored by Wright State University.
NCT05287724 is a Early Phase 1 study of Pruritus and Skin Disorder that has completed, run by Wright State University. The registered enrollment target is 20 participants, below the 109-participant average among 12 other Pruritus trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05287724, a Early Phase 1 study of Pruritus and Skin Disorder, has completed, sponsored by Wright State University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this double-blinded placebo-controlled cross-over study is to define the role of the over the counter agent, N-acetyl cysteine (NAC), in mitigating the development of pruritus (skin itching). The study is designed to have all subjects treated with a seven-day regimen of both NAC and placebo. NAC will be prescribed at a dose of 1,500 mg twice daily for seven days. Subjects will initially be randomly assigned (1:1) to either the NAC or placebo arm of the study, before crossing over to the opposite arm after completing a minimum of 30-day washout period. The study will encompass a period of approximately 11 weeks (about 2 and a half months).
Primary Outcome
The change will be assessed from the Skin Pain Visual Analogue Scale (0 = no skin pain to 10 = severe skin pain).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG N-acetyl cysteine
Study Locations (1)
Ohio
- Wright State Physicians - Fairborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-06-19 |
| Est. Completion | 2024-01-04 |
| Phase | Early Phase 1 |
What the finished NCT05287724 record still lists
NCT05287724 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 109-participant average among 12 other Pruritus trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Pruritus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05287724 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05287724 about?
NCT05287724 is a clinical study titled "Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli". The objective of this double-blinded placebo-controlled cross-over study is to define the role of the over the counter agent, N-acetyl cysteine (NAC), in mitigating the development of pruritus (skin itching). The study is designed to have all subjects treated with a seven-day regimen of both NAC and...
What is the current status of trial NCT05287724?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2022-06-19. Estimated completion is 2024-01-04.
What conditions does trial NCT05287724 study?
This clinical trial studies the following conditions: Pruritus, Skin Disorder.
What interventions are being tested in trial NCT05287724?
The interventions under investigation include: Placebo (DRUG), N-acetyl cysteine (DRUG).
Who is sponsoring clinical trial NCT05287724?
This trial is sponsored by Wright State University, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05287724 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pruritus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05287724's enrollment target sits among peer trials
20 10th of 12 higher than 3 of 12 other Pruritus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pruritus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
VR-PMR for Post-Burn Symptoms
RECRUITING · NA
-
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
RECRUITING · Phase 3
-
Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch
RECRUITING · NA
-
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
COMPLETED · Phase 2
-
Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI